enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.

Read more..

Current and Future Treatments for Waldenstrom Macroglobulinemia

Current and Future Treatments for Waldenstrom Macroglobulinemia

What are the treatments for Waldenstrom macroglobulinemia and what's in the pipeline? Can Waldenstrom patients plan for a higher quality of life? Dr. Jorge Castillo, Clinical Director, Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, presents an overview of his presentation at the 2020 IWMF with Patient Power co-founder Andrew Schorr.

Read more..

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast.

Read more..

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos present a summary of trial findings and details regarding various BTK inhibitors, including ibrutinib, zanubrutinib, acalabrutinib, tirabrutinib, LOXO-305, etc.

Read more..

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). The Prescription Drug User Fee Act (PDUFA) target action date is October 18, 2021.

Read more..

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

December 21, 2020: Dr. Jorge Castillo walks us through immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis–and finally, how to talk to patients about them.

Read more..

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

Dear IMS Member: We hope you are well during these difficult times. As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance.

Read more..

Cancer and the COVID-19 Vaccine

Cancer and the COVID-19 Vaccine

On January 27, Dana Farber held a webinar to review the information regarding COVID-19 vaccinations for patients. Catherine Flynn (from the Bing Center Clinic) shares the following highlights from the webinar.  Note, the entire webinar was recorded and posted to Facebook, using the following link:

Read more..

COVID-19 Facts and Resources

COVID-19 Facts and Resources

Based on the latest guidance we have received from the state of Massachusetts, we expect Dana-Farber's supply of COVID-19 vaccine for patients to be very limited in February and perhaps longer. We are working hard to place special focus on getting vaccines to our most at-risk patients, in compliance with the state's rollout guidelines, as we receive allotments of the vaccine.

Read more..

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Please join the Center for Multiple Myeloma for a free webinar for patients and families to learn about the most recent updates in muliple myeloma and Waldenstrom's macroglobulinemia including the impact of COVID-19 and vaccination.

Read more..